ArticleCancer reports (Hoboken, N.J.)2026
Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent fifth edition of World Health Organization and International Consensus Classification in 2022 recognized TP53-mutated myelodysplastic neoplasms (MDS) as a distinct entity requiring multi-hit classification. Literatures indicate that TP53 variant alle frequency (VAF) correlates with clinical outcomes. However, comprehensive studies that characterize the full mutation landscape and clinical correlations in Asian populations are still limited.
aimsThis research aims to elucidate the mutation spectrum and baseline characteristics of TP53-mutated MDS in a Chinese cohort, thereby enhancing clinical understanding and treatment approaches. METHODS AND
resultsA total of 161 TP53-mutated patients from 1589 newly diagnosed MDS with next-generation sequencing (NGS) data via a targeted 96-gene sequencing panel were analyzed to assess genomic alterations. Among 161 TP53-mutated patients (10.1% of 1589 MDS cases), we identified a predominance of missense mutations (76.9%) and frequent co-occurrence with epigenetic modifiers, notably DNMT3A (11.8%), TET2 (10.6%), and ASXL1 (9.3%). Critically, TP53 VAF correlated strongly with disease severity parameters, including hemoglobin levels, blast percentage, karyotype, and International Prognostic Scoring System (IPSS), revised IPSS (IPSS-R) risk and IPSS-Molecular (IPSS-M) classifications (all p < 0.05), suggesting that TP53 VAF serves as an important biomarker for risk stratification. In addition, patients with multiple TP53 mutations harbored significantly worse IPSS, IPSS-R, and IPSS-M risk classifications compared to those with a single TP53 mutation.
conclusionsThis study underscores the importance of TP53 mutations in Asian MDS patients, contributing to genetic profiling in risk stratification and therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.